RESUMO
BACKGROUND: The prevalence of hypertension among black African patients is high, and these patients usually need two or more medications for blood-pressure control. However, the most effective two-drug combination that is currently available for blood-pressure control in these patients has not been established. METHODS: In this randomized, single-blind, three-group trial conducted in six countries in sub-Saharan Africa, we randomly assigned 728 black patients with uncontrolled hypertension (≥140/90 mm Hg while the patient was not being treated or was taking only one antihypertensive drug) to receive a daily regimen of 5 mg of amlodipine plus 12.5 mg of hydrochlorothiazide, 5 mg of amlodipine plus 4 mg of perindopril, or 4 mg of perindopril plus 12.5 mg of hydrochlorothiazide for 2 months. Doses were then doubled (10 and 25 mg, 10 and 8 mg, and 8 and 25 mg, respectively) for an additional 4 months. The primary end point was the change in the 24-hour ambulatory systolic blood pressure between baseline and 6 months. RESULTS: The mean age of the patients was 51 years, and 63% were women. Among the 621 patients who underwent 24-hour blood-pressure monitoring at baseline and at 6 months, those receiving amlodipine plus hydrochlorothiazide and those receiving amlodipine plus perindopril had a lower 24-hour ambulatory systolic blood pressure than those receiving perindopril plus hydrochlorothiazide (between-group difference in the change from baseline, -3.14 mm Hg; 95% confidence interval [CI], -5.90 to -0.38; P = 0.03; and -3.00 mm Hg; 95% CI, -5.8 to -0.20; P = 0.04, respectively). The difference between the group receiving amlodipine plus hydrochlorothiazide and the group receiving amlodipine plus perindopril was -0.14 mm Hg (95% CI, -2.90 to 2.61; P=0.92). Similar differential effects on office and ambulatory diastolic blood pressures, along with blood-pressure control and response rates, were apparent among the three groups. CONCLUSIONS: These findings suggest that in black patients in sub-Saharan Africa, amlodipine plus either hydrochlorothiazide or perindopril was more effective than perindopril plus hydrochlorothiazide at lowering blood pressure at 6 months. (Funded by GlaxoSmithKline Africa Noncommunicable Disease Open Lab; CREOLE ClinicalTrials.gov number, NCT02742467.).
Assuntos
Anlodipino/administração & dosagem , Anti-Hipertensivos/administração & dosagem , Hidroclorotiazida/administração & dosagem , Hipertensão/tratamento farmacológico , Perindopril/administração & dosagem , Adulto , África Subsaariana , Idoso , Anlodipino/efeitos adversos , Anti-Hipertensivos/efeitos adversos , População Negra , Pressão Sanguínea/efeitos dos fármacos , Combinação de Medicamentos , Quimioterapia Combinada , Feminino , Humanos , Hidroclorotiazida/efeitos adversos , Hipertensão/etnologia , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Perindopril/efeitos adversos , Método Simples-CegoRESUMO
BACKGROUND: Current hypertension guidelines recommend the use of combination therapy as first-line treatment or early in the management of hypertensive patients. Although there are many possible combinations of blood pressure(BP)-lowering therapies, the best combination for the black population is still a subject of debate because no large randomized controlled trials have been conducted in this group to compare the efficacy of different combination therapies to address this issue. METHODS: The comparison of 3 combination therapies in lowering BP in the black Africans (CREOLE) study is a randomized single-blind trial that will compare the efficacy of amlodipine plus hydrochlorothiazide versus amlodipine plus perindopril and versus perindopril plus hydrochlorothiazide in blacks residing in sub-Saharan Africa (SSA). Seven hundred two patients aged 30-79â¯years with a sitting systolic BP of 140 mm Hg and above, and less than 160â¯mm Hg on antihypertensive monotherapy, or sitting systolic BP of 150â¯mm Hg and above, and less than 180â¯mm Hg on no treatment, will be centrally randomized into any of the 3 arms (234 into each arm). The CREOLE study is taking place in 10 sites in SSA, and the primary outcome measure is change in ambulatory systolic BP from baseline to 6â¯months. The first patient was randomized in June 2017, and the trial will be concluded by 2019. CONCLUSIONS: The CREOLE trial will provide unique information as to the most efficacious 2-drug combination in blacks residing in SSA and thereby inform the development of clinical guidelines for the treatment of hypertension in this subregion.
Assuntos
Anlodipino/uso terapêutico , Anti-Hipertensivos/uso terapêutico , População Negra , Hidroclorotiazida/uso terapêutico , Hipertensão/tratamento farmacológico , Hipertensão/etnologia , Perindopril/uso terapêutico , Adulto , África Subsaariana , Idoso , Combinação de Medicamentos , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Projetos de Pesquisa , Método Simples-CegoRESUMO
BACKGROUND: There are few contemporary data on the mortality and morbidity associated with rheumatic heart disease or information on their predictors. We report the 2-year follow-up of individuals with rheumatic heart disease from 14 low- and middle-income countries in Africa and Asia. METHODS: Between January 2010 and November 2012, we enrolled 3343 patients from 25 centers in 14 countries and followed them for 2 years to assess mortality, congestive heart failure, stroke or transient ischemic attack, recurrent acute rheumatic fever, and infective endocarditis. RESULTS: Vital status at 24 months was known for 2960 (88.5%) patients. Two-thirds were female. Although patients were young (median age, 28 years; interquartile range, 18-40), the 2-year case fatality rate was high (500 deaths, 16.9%). Mortality rate was 116.3/1000 patient-years in the first year and 65.4/1000 patient-years in the second year. Median age at death was 28.7 years. Independent predictors of death were severe valve disease (hazard ratio [HR], 2.36; 95% confidence interval [CI], 1.80-3.11), congestive heart failure (HR, 2.16; 95% CI, 1.70-2.72), New York Heart Association functional class III/IV (HR, 1.67; 95% CI, 1.32-2.10), atrial fibrillation (HR, 1.40; 95% CI, 1.10-1.78), and older age (HR, 1.02; 95% CI, 1.01-1.02 per year increase) at enrollment. Postprimary education (HR, 0.67; 95% CI, 0.54-0.85) and female sex (HR, 0.65; 95% CI, 0.52-0.80) were associated with lower risk of death. Two hundred and four (6.9%) patients had new congestive heart failure (incidence, 38.42/1000 patient-years), 46 (1.6%) had a stroke or transient ischemic attack (8.45/1000 patient-years), 19 (0.6%) had recurrent acute rheumatic fever (3.49/1000 patient-years), and 20 (0.7%) had infective endocarditis (3.65/1000 patient-years). Previous stroke and older age were independent predictors of stroke/transient ischemic attack or systemic embolism. Patients from low- and lower-middle-income countries had significantly higher age- and sex-adjusted mortality than patients from upper-middle-income countries. Valve surgery was significantly more common in upper-middle-income than in lower-middle- or low-income countries. CONCLUSIONS: Patients with clinical rheumatic heart disease have high mortality and morbidity despite being young; those from low- and lower-middle-income countries had a poorer prognosis associated with advanced disease and low education. Programs focused on early detection and the treatment of clinical rheumatic heart disease are required to improve outcomes.
Assuntos
Endocardite/mortalidade , Insuficiência Cardíaca/mortalidade , Sistema de Registros , Cardiopatia Reumática/mortalidade , Acidente Vascular Cerebral/mortalidade , Adolescente , Adulto , África/epidemiologia , Fatores Etários , Ásia/epidemiologia , Países em Desenvolvimento , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
BACKGROUND: Tuberculous pericarditis is associated with high morbidity and mortality even if antituberculosis therapy is administered. We evaluated the effects of adjunctive glucocorticoid therapy and Mycobacterium indicus pranii immunotherapy in patients with tuberculous pericarditis. METHODS: Using a 2-by-2 factorial design, we randomly assigned 1400 adults with definite or probable tuberculous pericarditis to either prednisolone or placebo for 6 weeks and to either M. indicus pranii or placebo, administered in five injections over the course of 3 months. Two thirds of the participants had concomitant human immunodeficiency virus (HIV) infection. The primary efficacy outcome was a composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis. RESULTS: There was no significant difference in the primary outcome between patients who received prednisolone and those who received placebo (23.8% and 24.5%, respectively; hazard ratio, 0.95; 95% confidence interval [CI], 0.77 to 1.18; P=0.66) or between those who received M. indicus pranii immunotherapy and those who received placebo (25.0% and 24.3%, respectively; hazard ratio, 1.03; 95% CI, 0.82 to 1.29; P=0.81). Prednisolone therapy, as compared with placebo, was associated with significant reductions in the incidence of constrictive pericarditis (4.4% vs. 7.8%; hazard ratio, 0.56; 95% CI, 0.36 to 0.87; P=0.009) and hospitalization (20.7% vs. 25.2%; hazard ratio, 0.79; 95% CI, 0.63 to 0.99; P=0.04). Both prednisolone and M. indicus pranii, each as compared with placebo, were associated with a significant increase in the incidence of cancer (1.8% vs. 0.6%; hazard ratio, 3.27; 95% CI, 1.07 to 10.03; P=0.03, and 1.8% vs. 0.5%; hazard ratio, 3.69; 95% CI, 1.03 to 13.24; P=0.03, respectively), owing mainly to an increase in HIV-associated cancer. CONCLUSIONS: In patients with tuberculous pericarditis, neither prednisolone nor M. indicus pranii had a significant effect on the composite of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis. (Funded by the Canadian Institutes of Health Research and others; IMPI ClinicalTrials.gov number, NCT00810849.).
Assuntos
Glucocorticoides/uso terapêutico , Imunoterapia , Mycobacterium , Pericardite Tuberculosa/tratamento farmacológico , Prednisolona/uso terapêutico , Adulto , Tamponamento Cardíaco/etiologia , Tamponamento Cardíaco/prevenção & controle , Terapia Combinada , Feminino , Glucocorticoides/efeitos adversos , Infecções por HIV/complicações , Humanos , Estimativa de Kaplan-Meier , Masculino , Mycobacterium/imunologia , Pericardiocentese , Pericardite Constritiva/etiologia , Pericardite Constritiva/prevenção & controle , Pericardite Tuberculosa/complicações , Pericardite Tuberculosa/mortalidade , Prednisolona/efeitos adversos , Falha de TratamentoRESUMO
AIMS: Rheumatic heart disease (RHD) accounts for over a million premature deaths annually; however, there is little contemporary information on presentation, complications, and treatment. METHODS AND RESULTS: This prospective registry enrolled 3343 patients (median age 28 years, 66.2% female) presenting with RHD at 25 hospitals in 12 African countries, India, and Yemen between January 2010 and November 2012. The majority (63.9%) had moderate-to-severe multivalvular disease complicated by congestive heart failure (33.4%), pulmonary hypertension (28.8%), atrial fibrillation (AF) (21.8%), stroke (7.1%), infective endocarditis (4%), and major bleeding (2.7%). One-quarter of adults and 5.3% of children had decreased left ventricular (LV) systolic function; 23% of adults and 14.1% of children had dilated LVs. Fifty-five percent (n = 1761) of patients were on secondary antibiotic prophylaxis. Oral anti-coagulants were prescribed in 69.5% (n = 946) of patients with mechanical valves (n = 501), AF (n = 397), and high-risk mitral stenosis in sinus rhythm (n = 48). However, only 28.3% (n = 269) had a therapeutic international normalized ratio. Among 1825 women of childbearing age (12-51 years), only 3.6% (n = 65) were on contraception. The utilization of valvuloplasty and valve surgery was higher in upper-middle compared with lower-income countries. CONCLUSION: Rheumatic heart disease patients were young, predominantly female, and had high prevalence of major cardiovascular complications. There is suboptimal utilization of secondary antibiotic prophylaxis, oral anti-coagulation, and contraception, and variations in the use of percutaneous and surgical interventions by country income level.
Assuntos
Cardiopatia Reumática/terapia , Administração Oral , Adulto , Distribuição por Idade , Antibacterianos/uso terapêutico , Antibioticoprofilaxia , Anticoagulantes/administração & dosagem , Estudos Transversais , Países em Desenvolvimento , Medicina Baseada em Evidências , Feminino , Saúde Global , Doenças das Valvas Cardíacas/epidemiologia , Doenças das Valvas Cardíacas/etiologia , Doenças das Valvas Cardíacas/terapia , Humanos , Masculino , Penicilinas/uso terapêutico , Projetos Piloto , Estudos Prospectivos , Cardiopatia Reumática/complicações , Cardiopatia Reumática/epidemiologia , Distribuição por SexoRESUMO
BACKGROUND: In spite of antituberculosis chemotherapy, tuberculous (TB) pericarditis causes death or disability in nearly half of those affected. Attenuation of the inflammatory response in TB pericarditis may improve outcome by reducing cardiac tamponade and pericardial constriction, but there is uncertainty as to whether adjunctive immunomodulation with corticosteroids and Mycobacterium w (M. w) can safely reduce mortality and morbidity. OBJECTIVES: The primary objective of the IMPI Trial is to assess the effectiveness and safety of prednisolone and M. w immunotherapy in reducing the composite outcome of death, constriction, or cardiac tamponade requiring pericardial drainage in 1,400 patients with TB pericardial effusion. DESIGN: The IMPI trial is a multicenter international randomized double-blind placebo-controlled 2 × 2 factorial study. Eligible patients are randomly assigned to receive oral prednisolone or placebo for 6 weeks and M. w injection or placebo for 3 months. Patients are followed up at weeks 2, 4, and 6 and months 3 and 6 during the intervention period and 6-monthly thereafter for up to 4 years. The primary outcome is the first occurrence of death, pericardial constriction, or cardiac tamponade requiring pericardiocentesis. The secondary outcome is safety of immunomodulatory treatment measured by effect on opportunistic infections (eg, herpes zoster) and malignancy (eg, Kaposi sarcoma) and impact on measures of immunosuppression and the incidence of immune reconstitution disease. CONCLUSIONS: IMPI is the largest trial yet conducted comparing adjunctive immunotherapy in pericarditis. Its results will define the role of adjunctive corticosteroids and M. w immunotherapy in patients with TB pericardial effusion.
Assuntos
Vacinas Bacterianas/uso terapêutico , Imunoterapia/métodos , Mycobacterium/imunologia , Derrame Pericárdico/cirurgia , Pericardiocentese/métodos , Pericardite Tuberculosa/tratamento farmacológico , Prednisolona/administração & dosagem , Corticosteroides/uso terapêutico , Idoso , Antituberculosos/uso terapêutico , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Derrame Pericárdico/etiologia , Pericardite Tuberculosa/complicações , Pericardite Tuberculosa/cirurgia , Projetos Piloto , Estudos Prospectivos , Resultado do TratamentoRESUMO
Bioluminescent bays and lagoons are unique natural environments and popular tourist attractions. However, the bioluminescence in many of these water bodies has declined, principally due to anthropogenic activities. In the Caribbean, the bioluminescence in these bays and lagoons is mostly produced by the dinoflagellate Pyrodinium bahamense var. bahamense. Laguna Grande is one of the three year-round bioluminescent water bodies in Puerto Rico that are known to remain but P. bahamense var. bahamense density fluctuations have not been studied. In this study we describe water quality parameters and density fluctuations of the most common dinoflagellates in Laguna Grande, P. bahamense var. bahamense and Ceratium furca, over a three-year period. For this, three sampling stations were established in Laguna Grande from which water samples were collected in triplicate and analyzed for temperature, phosphates, nitrates, salinity, water transparency, fluorescence, and dinoflagellate densities, at the water surface and at 2m depth, from May 2003 to May 2006. The results showed a density fluctuation pattern for P. bahamense var. bahamense, where higher densities were observed mainly from April to September, and lower densities from October to February. Density fluctuations of C. furca were more erratic and a repetitive pattern was not observed. Densities of P. bahamense var. bahamense ranged from 0.48 to 90978 cells/L and densities of C. furca ranged from 0 to 11,200 cells/L. The mean population density throughout the sampling period was significantly higher in P. bahamense var. bahamense (mean = 18,958.5 cells/L) than in C. furca (mean = 2601.9 cells/L). Population densities of P. bahamense var. bahamense were negatively correlated with C. furca densities during the first year of sampling; however, they were positively correlated during the third year. Non-significant differences between surface and 2m depth samples were observed for temperature, phosphates, nitrates, salinity, fluorescence, and densities of P. bahamense var. bahamense and C. furca, suggesting a vertically mixed water column. Water transparency was positively correlated with salinity and negatively correlated with fluorescence. Fluorescence was negatively correlated with salinity. The mean population densities of P. bahamense var. bahamense and C. furca observed in this study were within the range of previous reports in other bioluminescent water bodies in Puerto Rico and Florida, U.S.A. In order to conserve the continuous P. bahamense var. bahamense populations in Laguna Grande, as well as its bioluminescence, it is recommended to maintain the existing water flow levels in the 1.5 km long inlet/outlet channel; to maintain unpolluted water quality parameters within the bay, the hydrographical basin and adjacent waters, and to preserve mangrove communities within the basin and adjacent areas. Results of this study may help to develop management plans aiming to conserve P. bahamense, its bioluminescence and the lagoon attraction.
Assuntos
Dinoflagellida/crescimento & desenvolvimento , Dinoflagellida/classificação , Monitoramento Ambiental , Lagos , Densidade Demográfica , Dinâmica Populacional , Porto Rico , Estações do Ano , TemperaturaRESUMO
Background: In the Investigation of the Management of Pericarditis (IMPI) randomized control, 2x2 factorial trial, Mycobacterium indicus pranii (MIP) immunotherapy, adjunctive corticosteroids or MIP combined with corticosteroids was compared to standard tuberculosis (TB) therapy for tuberculous pericarditis (TBP). While MIP and/or the combination of MIP and corticosteroids had no impact on all-cause mortality or pericarditis related outcomes, corticosteroids reduced the incidence of constrictive pericarditis at 12 months. Data suggests that both adjunctive therapies modulate the immune and inflammatory responses to pulmonary TB. Whether they affect systemic antigen-specific T cell responses, key immune mediators of Mycobacterium tuberculosis control, in patients with TBP is unknown. Methods: Participants with definite or probable TBP were randomly assigned to receive five injections of MIP or placebo at 2-week intervals and either 6 weeks of oral prednisolone or placebo. Frequencies of CD4 and CD8 T cells expressing IFN-γ, IL-2 or TNF in response to MIP or purified protein derivative stimulation were measured by intracellular cytokine staining and flow cytometry up to 24 weeks post treatment. Results: Immunotherapy with MIP did not significantly modulate frequencies of Th1 CD4 and CD8 T cells compared to placebo. Adjunctive prednisolone also did not change mycobacteria-specific CD4 or CD8 T cell responses. By contrast, combinatorial therapy with MIP and prednisolone was associated with a modest increase in frequencies of multifunctional and single cytokine-expressing CD4 T cell responses at 6 and 24 weeks post treatment. Conclusions: Consistent with the lack of a significant clinical effect in the IMPI trial, MIP immunotherapy did not significantly modulate mycobacteria-specific T cell responses. Despite the positive effect of prednisolone on hospitalizations and constrictive pericarditis in the IMPI trial, prednisolone did not significantly reduce pro-inflammatory T cell responses in this sub-study. The modest improvement of mycobacteria-specific T cell upon combinatorial therapy with MIP and prednisolone requires further investigation.
RESUMO
BACKGROUND: We sought to address the paucity of data to support the evidence-based management of hypertension to achieve optimal blood pressure (BP) control on a sex-specific basis in Africa. METHODS: We undertook a post hoc analysis of the multicenter, randomized CREOLE (Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans) Trial to test the hypothesis that there would be clinically important differences in office BP control between African men and women. We compared the BP levels of 397 and 238 hypertensive women (63%, 50.9 ± 10.5 years) and men (51.2 ± 11.3 years) from 10 sites across sub-Saharan Africa who completed baseline and 6-month profiling according to their randomly allocated antihypertensive treatment. RESULTS: Overall, 442/635 (69.6%) participants achieved an office BP target of <140/90 mm Hg at 6 months; comprising more women (286/72.0%) than men (156/65.5%) (adjusted odds ratio [OR] 1.59, 95% confidence interval [CI] 1.07-2.39; P = 0.023). Women randomized to amlodipine-hydrochlorothiazide (HCTZ) (adjusted OR 3.03, 95% CI 1.71-5.35; P < 0.001) or amlodipine-perindopril (adjusted OR 2.62, 95% CI 1.49-4.58; P = 0.01) were more likely to achieve this target compared with perindopril-HCTZ. Among men, there were no equivalent treatment differences-amlodipine-HCTZ (OR 1.54, 95% CI 0.76-3.12; P = 0.23) or amlodipine-perindopril (OR 1.32, 95% CI 0.65-2.67; P = 0.44) vs. perindopril-HCTZ. Among the 613 participants (97%) with 24-hour ambulatory BP monitoring, women had significantly lower systolic (124.1 ± 18.1 vs. 127.3 ± 16.9; P = 0.028) and diastolic (72.7 ± 10.4 vs. 75.1 ± 10.5; P = 0.007) BP levels at 6 months compared with men. CONCLUSIONS: These data suggest clinically important differences in the therapeutic response to antihypertensive combination therapy among African women compared with African men.
Assuntos
Hipertensão , Perindopril , Anlodipino , Anti-Hipertensivos/farmacologia , População Negra , Pressão Sanguínea , Método Duplo-Cego , Combinação de Medicamentos , Quimioterapia Combinada , Feminino , Humanos , Hidroclorotiazida/uso terapêutico , Hipertensão/diagnóstico , Hipertensão/tratamento farmacológico , Masculino , Perindopril/uso terapêutico , Resultado do TratamentoRESUMO
BACKGROUND: The effect of 3 commonly recommended combinations of anti-hypertensive agents-amlodipine plus hydrochlorothiazide (calcium channel blocker [CCB]+thiazide), amlodipine plus perindopril (CCB+ACE [angiotensin-converting enzyme]-inhibitor), and perindopril plus hydrochlorothiazide (ACE-inhibitor+thiazide) on blood pressure variability (V) are unknown. METHODS: We calculated the blood pressure variability (BPV) in 405 patients (130, 146, and 129 randomized to ACE-inhibitor+thiazide, CCB+thiazide, and CCB+ACE-inhibitor, respectively) who underwent ambulatory blood pressure monitoring after 6 months of treatment in the Comparisons of Three Combinations Therapies in Lowering Blood Pressure in Black Africans trial (CREOLE) of Black African patients. BPV was calculated using the SD of 30-minute interval values for 24-hour ambulatory BPs and for confirmation using the coefficient of variation. Linear mixed model regression was used to calculate mean differences in BPV between treatment arms. Within-clinic BPV was also calculated from the mean SD and coefficient of variation of 3 readings at clinic visits. RESULTS: Baseline distributions of age, sex, and blood pressure parameters were similar across treatment groups. Participants were predominately male (62.2%) with mean age 50.4 years. Those taking CCB+thiazide had significantly reduced ambulatory systolic and diastolic BPV compared with those taking ACE-inhibitor+thiazide. The CCB+thiazide and CCB+ACE-inhibitor groups showed similar BPV. Similar patterns of BPV were apparent among groups using within-clinic blood pressures and when assessed by coefficient of variation. CONCLUSIONS: Compared with CCB-containing combinations, ACE-inhibitor plus thiazide was associated with higher levels, generally significant, of ambulatory and within-clinic systolic and diastolic BPV. These results supplement the differential ambulatory blood pressure-lowering effects of these therapies in the CREOLE trial.
Assuntos
Hipertensão , Perindopril , Humanos , Masculino , Pessoa de Meia-Idade , Perindopril/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Anti-Hipertensivos/farmacologia , Pressão Sanguínea , Monitorização Ambulatorial da Pressão Arterial , Hipertensão/diagnóstico , Hipertensão/tratamento farmacológico , Hipertensão/complicações , Quimioterapia Combinada , Anlodipino/uso terapêutico , Anlodipino/farmacologia , Hidroclorotiazida/uso terapêutico , Hidroclorotiazida/farmacologia , Bloqueadores dos Canais de Cálcio/uso terapêutico , Bloqueadores dos Canais de Cálcio/farmacologia , Combinação de Medicamentos , Tiazidas/uso terapêutico , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Inibidores da Enzima Conversora de Angiotensina/farmacologiaRESUMO
BACKGROUND: The survival of incident dialysis patients' end-stage kidney disease in some European and American has been reported to improve in modern era compared to earlier periods. However, in Ireland, this has not been well documented. AIM: To investigate the survival outcomes of incident end-stage kidney failure dialysis patients in a tertiary center over a 24-year period, 1993-2017. METHODS: A retrospective analysis was carried out utilizing the Beaumont Hospital Renal Database. Consecutive adults with incident dialysis were analyzed. Kaplan-Meier methods and the estimated mean survival times were used to evaluate survival at successive 4-year periods of time. RESULTS: In total, 2106 patients were included, of whom 830 underwent subsequent renal transplantation during follow-up. During the study period, from 1993 up to 2017, the mean patients' age increased from 56.3 ± 17.4 in 1993-1996 to 60.6 ± 18.3 in 2014-2017. There was an overall decrement in mortality over successive time intervals which were mirrored by the improvements in median survival after commencement of dialysis treatment from 6.14 years during 1993-1996 to 8.01 years during 2009-2012. Patients' survival has steadily improved, with the 5-year survival has risen over time, by almost 15%. This positive signal persisted and became more pronounced after adjusting Kaplan-Meier curve to age, where the 5-year survival estimates were exceeding 80% in 2014-2017. CONCLUSION: Survival rates among incident dialysis patients have improved progressively between 1993 and 2017 in Beaumont Hospital in Dublin, Ireland. The factors which led to this improvement are not entirely clear, but likely to be multifactorial.
Assuntos
Falência Renal Crônica , Transplante de Rim , Humanos , Irlanda/epidemiologia , Estimativa de Kaplan-Meier , Falência Renal Crônica/terapia , Diálise Renal , Estudos Retrospectivos , Fatores de Risco , Taxa de SobrevidaRESUMO
BACKGROUND: Heart failure (HF), the dominant form of cardiovascular disease in Africans, is mainly due to hypertension, rheumatic heart disease and cardiomyopathy. Cardiomyopathies pose a great challenge because of poor prognosis and high prevalence in low- and middle-income countries (LMICs). Little is known about the etiology and outcome of cardiomyopathy in Africa. Specifically, the role of myocarditis and the genetic causes of cardiomyopathy are largely unidentified in Africans. METHOD: The African Cardiomyopathy and Myocarditis Registry Program (the IMHOTEP study) is a pan-African multi-centre, hospital-based cohort study, designed with the primary aim of describing the clinical characteristics, genetic causes, prevalence, management and outcome of cardiomyopathy and myocarditis in children and adults. The secondary aim is to identify barriers to the implementation of evidence-based care and provide a platform for trials and other intervention studies to reduce morbidity and mortality in cardiomyopathy. The registry consists of a prospective cohort of newly diagnosed (i.e., incident) cases and a retrospective (i.e., prevalent) cohort of existing cases from participating centres. Patients with cardiomyopathy and myocarditis will be subjected to a standardized 3-stage diagnostic process. To date, 750 patients have been recruited into the multi-centre pilot phase of the study. CONCLUSION: The IMHOTEP study will provide comprehensive and novel data on clinical features, genetic causes, prevalence and outcome of African children and adults with all forms of cardiomyopathy and myocarditis in Africa. Based on these findings, appropriate strategies for management and prevention of the cardiomyopathies in LMICs are likely to emerge.
Assuntos
Cardiomiopatias , Miocardite , Adulto , África/epidemiologia , Cardiomiopatias/diagnóstico , Cardiomiopatias/epidemiologia , Cardiomiopatias/genética , Criança , Estudos de Coortes , Humanos , Miocardite/diagnóstico , Miocardite/epidemiologia , Miocardite/terapia , Estudos Prospectivos , Sistema de Registros , Estudos RetrospectivosRESUMO
BACKGROUND: There is exponential growth in the interest and implementation of genomics research in Africa. This growth has been facilitated by the Human Hereditary and Health in Africa (H3Africa) initiative, which aims to promote a contemporary research approach to the study of genomics and environmental determinants of common diseases in African populations. OBJECTIVE: The purpose of this article is to describe important challenges affecting genomics research implementation in Africa. METHODS: The observations, challenges and recommendations presented in this article were obtained through discussions by African scientists at teleconferences and face-to-face meetings, seminars at consortium conferences and in-depth individual discussions. RESULTS: Challenges affecting genomics research implementation in Africa, which are related to limited resources include ill-equipped facilities, poor accessibility to research centers, lack of expertise and an enabling environment for research activities in local hospitals. Challenges related to the research study include delayed funding, extensive procedures and interventions requiring multiple visits, delays setting up research teams and insufficient staff training, language barriers and an underappreciation of cultural norms. While many African countries are struggling to initiate genomics projects, others have set up genomics research facilities that meet international standards. CONCLUSIONS: The lessons learned in implementing successful genomics projects in Africa are recommended as strategies to overcome these challenges. These recommendations may guide the development and application of new research programs in low-resource settings.
Assuntos
Genômica/organização & administração , Pesquisa/organização & administração , África , Barreiras de Comunicação , Competência Cultural , Meio Ambiente , Organização do Financiamento , Humanos , Capacitação em Serviço , Idioma , Pesquisa/economiaRESUMO
BACKGROUND: Existing clinical decision rules (CDRs) to diagnose group A streptococcal (GAS) pharyngitis have not been validated in sub-Saharan Africa. We developed a locally applicable CDR while evaluating existing CDRs for diagnosing GAS pharyngitis in South African children. METHODS: We conducted a prospective cohort study and enrolled 997 children 3-15 years of age presenting to primary care clinics with a complaint of sore throat, and whose parents provided consent. Main outcome measures were signs and symptoms of pharyngitis and a positive GAS culture from a throat swab. Bivariate and multivariate analyses were used to develop the CDR. In addition, the diagnostic effectiveness of 6 existing rules for predicting a positive culture in our cohort was assessed. RESULTS: A total of 206 of 982 children (21%) had a positive GAS culture. Tonsillar swelling, tonsillar exudates, tender or enlarged anterior cervical lymph nodes, absence of cough and absence of rhinorrhea were associated with positive cultures in bivariate and multivariate analyses. Four variables (tonsillar swelling and one of tonsillar exudate, no rhinorrhea, no cough), when used in a cumulative score, showed 83.7% sensitivity and 32.2% specificity for GAS pharyngitis. Of existing rules tested, the rule by McIsaac et al had the highest positive predictive value (28%), but missed 49% of the culture-positive children who should have been treated. CONCLUSION: The new 4-variable CDR for GAS pharyngitis (ie, tonsillar swelling and one of tonsillar exudate, no rhinorrhea, no cough) outperformed existing rules for GAS pharyngitis diagnosis in children with symptomatic sore throat in Cape Town.
Assuntos
Faringite/diagnóstico , Infecções Estreptocócicas/diagnóstico , Streptococcus pyogenes , Criança , Sistemas de Apoio a Decisões Clínicas , Feminino , Humanos , Masculino , Faringite/microbiologia , Estudos Prospectivos , Índice de Gravidade de Doença , África do Sul , Infecções Estreptocócicas/microbiologiaRESUMO
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) remain major causes of heart failure, stroke and death among African women and children, despite being preventable and imminently treatable. From 21 to 22 February 2015, the Social Cluster of the Africa Union Commission (AUC) hosted a consultation with RHD experts convened by the Pan-African Society of Cardiology (PASCAR) in Addis Ababa, Ethiopia, to develop a 'roadmap' of key actions that need to be taken by governments to eliminate ARF and eradicate RHD in Africa. Seven priority areas for action were adopted: (1) create prospective disease registers at sentinel sites in affected countries to measure disease burden and track progress towards the reduction of mortality by 25% by the year 2025, (2) ensure an adequate supply of high-quality benzathine penicillin for the primary and secondary prevention of ARF/RHD, (3) improve access to reproductive health services for women with RHD and other non-communicable diseases (NCD), (4) decentralise technical expertise and technology for diagnosing and managing ARF and RHD (including ultrasound of the heart), (5) establish national and regional centres of excellence for essential cardiac surgery for the treatment of affected patients and training of cardiovascular practitioners of the future, (6) initiate national multi-sectoral RHD programmes within NCD control programmes of affected countries, and (7) foster international partnerships with multinational organisations for resource mobilisation, monitoring and evaluation of the programme to end RHD in Africa. This Addis Ababa communiqué has since been endorsed by African Union heads of state, and plans are underway to implement the roadmap in order to end ARF and RHD in Africa in our lifetime.
Assuntos
Prestação Integrada de Cuidados de Saúde/organização & administração , Prioridades em Saúde/organização & administração , Necessidades e Demandas de Serviços de Saúde/organização & administração , Avaliação das Necessidades/organização & administração , Prevenção Primária/organização & administração , Febre Reumática/prevenção & controle , Cardiopatia Reumática/prevenção & controle , Prevenção Secundária/organização & administração , África/epidemiologia , Antibacterianos/provisão & distribuição , Procedimentos Cirúrgicos Cardíacos , Comportamento Cooperativo , Acessibilidade aos Serviços de Saúde/organização & administração , Humanos , Cooperação Internacional , Penicilina G Benzatina/provisão & distribuição , Sistema de Registros , Febre Reumática/diagnóstico , Febre Reumática/epidemiologia , Cardiopatia Reumática/diagnóstico , Cardiopatia Reumática/epidemiologiaRESUMO
We report the case of a 45-year-old haemodialysis patient who achieved a sustained virological response (SVR) following pegylated interferon therapy for hepatitis C virus (HCV) genotype 2 infection. He was subsequently cohorted with other HCV-infected dialysis patients and became re-infected with HCV genotype 3a. Epidemiological and molecular investigations identified a highly viraemic HCV genotype 3a-infected dialysis patient as the likely source of this infection. This critical incident informed a revision to local and national infection control policy regarding the dialysis management of patients who achieve an SVR following anti-viral treatment.
RESUMO
Bioluminescent bays and lagoons are unique natural environments and popular tourist attractions. However, the bioluminescence in many of these water bodies has declined, principally due to anthropogenic activities. In the Caribbean, the bioluminescence in these bays and lagoons is mostly produced by the dinoflagellate Pyrodinium bahamense var. bahamense. Laguna Grande is one of the three year-round bioluminescent water bodies in Puerto Rico that are known to remain but P. bahamense var. bahamense density fluctuations have not been studied. In this study we describe water quality parameters and density fluctuations of the most common dinoflagellates in Laguna Grande, P. bahamense var. bahamense and Ceratium furca, over a three-year period. For this, three sampling stations were established in Laguna Grande from which water samples were collected in triplicate and analyzed for temperature, phosphates, nitrates, salinity, water transparency, fluorescence, and dinoflagellate densities, at the water surface and at 2m depth, from May 2003 to May 2006. The results showed a density fluctuation pattern for P. bahamense var. bahamense, where higher densities were observed mainly from April to September, and lower densities from October to February. Density fluctuations of C. furca were more erratic and a repetitive pattern was not observed. Densities of P. bahamense var. bahamense ranged from 0.48 to 90 978 cells/L and densities of C. furca ranged from 0 to 11 200 cells/L. The mean population density throughout the sampling period was significantly higher in P. bahamense var. bahamense (mean=18 958.5 cells/L) than in C. furca (mean=2 601.9 cells/L). Population densities of P. bahamense var. bahamense were negatively correlated with C. furca densities during the first year of sampling; however, they were positively correlated during the third year. Non-significant differences between surface and 2m depth samples were observed for temperature, phosphates, nitrates, salinity, fluorescence, and densities of P. bahamense var. bahamense and C. furca, suggesting a vertically mixed water column. Water transparency was positively correlated with salinity and negatively correlated with fluorescence. Fluorescence was negatively correlated with salinity. The mean population densities of P. bahamense var. bahamense and C. furca observed in this study were within the range of previous reports in other bioluminescent water bodies in Puerto Rico and Florida, USA. In order to conserve the continuous P. bahamense var. bahamense populations in Laguna Grande, as well as its bioluminescence, it is recommended to maintain the existing water flow levels in the 1.5km long inlet/outlet channel; to maintain unpolluted water quality parameters within the bay, the hydrographical basin and adjacent waters, and to preserve mangrove communities within the basin and adjacent areas. Results of this study may help to develop management plans aiming to conserve P. bahamense, its bioluminescence and the lagoon attraction.
Este estudio describe parámetros de calidad de agua y fluctuaciones en la densidad poblacional de Pyrodinium bahamense Plate 1906 y Ceratium furca (Ehrenberg) Claparède & Lachmann 1859, los dos dinoflagelados más abundantes en las bahías y lagunas bioluminiscentes de Puerto Rico, durante un periodo de tres años, en Laguna Grande, Puerto Rico. En P. bahamense se observó un patrón de densidad poblacional, donde se bservaron las densidades más altas mayormente desde abril hasta septiembre y las más bajas desde octubre hasta febrero. En C. furca las fluctuaciones en densidad fueron más erráticas y no se observó un patrón repetitivo. La densidad poblacional promedio de P. bahamense (media=18 958.5 células/L) fue significantemente mayor que la de C. furca (media=2 601.9 células/L). No se encontraron diferencias significantes entre las muestras de superficie y las de 2m de profundidad para temperatura, fosfatos, nitratos, salinidad, fluorescencia, y las densidades de P. bahamense y C. furca, lo que sugiere que la columna de agua está mezclada verticalmente. La densidad poblacional media de P. bahamense y C. furca en Laguna Grande está dentro del rango de las densidades que han sido reportadas para otras lagunas bioluminiscentes en Puerto Rico y Florida, EE.UU.
Assuntos
Dinoflagellida/crescimento & desenvolvimento , Dinoflagellida/classificação , Monitoramento Ambiental , Lagos , Densidade Demográfica , Dinâmica Populacional , Porto Rico , Estações do Ano , TemperaturaRESUMO
The discussion was initiated by a paper comparing the measurement of dialysis dose (Kt/V) and solute clearance using on-line ultra-violet absorbance, blood and dialysate urea and ionic dialysance by Uhlin et al (NDT 2006). Participants from 14 countries discussed the theory behind the UV absorbance technique and the potential for its use in routine practice, the correlation between Kt/V measured using different methods, the use of ionic dialysance and the optimisation of dose monitoring. The 'take-home' messages from the discussion were that UV-absorbance could help ensure the delivery of dialysis dose as it provides real time feedback on the effect interventions such as repositioning of needles. The technology is relatively inexpensive and requires no consumables but changes in the dialysis machine settings could lead to misleading measurements if not communicated to the UV monitor. Session-to-session variation in dialysis dose can be measured using on-line clearance monitoring. If it is already on the machine and costs nothing, why not use it? Alternatively, regular access recirculation checks and a record of the total blood volume processed at each session allow problems with delivered dialysis dose to be picked up between routine blood tests.